1[1]Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer, 2002,38(2) :240～257.
2[2]Siemann DW. 10th international conference on chemical modifiers on cancer treatment. Florida:USA, 1998: 56～102.
3[3]Shchepetkin IA. Generation of sanazole nitro radicals by xanthine oxidase. Biochemistry, 1998, 63 (12): 1378 ～ 1384.
4[4]Overgard J. Misonidazole combined with splitcourse radiothera py in the treatment of invasive carcinoma of larynx and phar ynx. Final report from the Dahance 2 study. In: 6th Int Conf on Chemical Modifiers of Cancer Treatment, Paris, France,1988:3～4.
5[5]Grigsby PW, Winter K, Wasserman TH, et al. Irradiation with or without misonidazole for patients with stages ⅢB orⅣA carcinoma of the cervix: final results of RTOG80～05. Int J Radiat Oncol Biol Phys, 1999, 44(3) :513～517.
6[6]Beard C, Buswell L, Rose MA. PhaseⅡ trial of external beam radiation with etanidazole(SR - 2508)for the treatment of local ly advanced prostate cancer. Int J Radiat Oncol Biol Phys,1994, 29(3) :611～616.
7[7]Hideko N, Masahiro B, Bando B, et al. Radiosensitizing,toxicological,and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemi calmodifiers. Int J Radiat Oncol Biol Phys, 1992, 22(3) :561～564.
8[8]Inomata T, Ogawa Y, Itoh S, et al. Lung metastasis suppres sion of the bifunctional new radiosensitizer KIN - 806. Int J Mol Med, 1999, 4(3):257～260.
9[9]Inomata T, Ogawa Y, Nishioka A, et al. The immunopotentia tion effects of the bifunctional radiosensitizer KIN-806 in comparison with its analogs KIN - 804 and KIN - 844. Oncol Rep,1999, 6(6) :1209～1212.
10INOMATA T,OGAWA Y,NISHIOKA A,et al.The immunopotenti-ation effects of the bifunctional radiosensitizer KIN-806 in corn-parison with its analogs KIN-8O4 anti KIN-844[J].Oncol Rep,1999,6(6):1209-1221.
